Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1995
Dystonia in a patient with deletion of 18qM F Gordon, S Bressman, M F Brin, et al.
Neurology|March 1, 1995
Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled studyT Mezaki, R Kaji, N Kohara, et al.
Acta Neurologica Scandinavica|August 1, 1992
Debrisoquine hydroxylation in Parkinson's diseaseM J Steiger, P Lledo, N P Quinn, et al.
Brain Research|May 4, 2001
Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brainR H Walker, M F Brin, D Sandu, et al.
Neuropharmacology|August 1, 1986
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal areaA J Bradbury, B Costall, P G Jenner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2000
Intrathecal baclofen for dystonia: benefits and complications during six years of experienceR H Walker, F O Danisi, D M Swope, et al.
Neurology|April 10, 2002
Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusionsR H Walker, S Morgello, B Davidoff-Feldman, et al.
Neuroscience Letters|July 31, 1985
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatmentA J Bradbury, B Costall, P G Jenner, et al.
Neuropharmacology|August 1, 1986
The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitorsA J Bradbury, B Costall, P G Jenner, et al.
European Journal of Neurology|March 18, 2014
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraineH-C Diener, D W Dodick, C C Turkel, et al.
Pageof 11